Ampersand Capital Partners Invests in Sterling Medical Devices

Ampersand Capital Partners Makes Growth Investment in Lexington Medical

April 17, 2025

Medical Devices

Ampersand Capital Partners has made a strategic growth investment in Lexington Medical, a Bedford, Massachusetts-based designer and manufacturer of minimally invasive surgical stapling devices. The investment will support Lexington's product innovation, smart manufacturing initiatives, and global market expansion while bolstering the company's US-based manufacturing and talent base.

Sterling Medical Devices Recapitalizes and Merges with RBC Medical Innovations

February 8, 2023

Medical Devices

Ampersand-backed Sterling Medical Devices recapitalized and merged with RBC Medical Innovations to create a combined electromechanical medical device design, development and manufacturing company. The transaction brings together complementary capabilities (including energy-based electromechanical device expertise and manufacturing) and appoints industry veteran David Montecalvo as CEO of the combined business.

Ampersand Capital Partners Majority Recapitalizes N2 Biomedical

June 18, 2019

Medical Devices

Ampersand Capital Partners completed a majority recapitalization of N2 Biomedical, a Bedford, Massachusetts-based provider of coating and surface treatment solutions for the medical device industry. The transaction positions N2 to accelerate growth and broaden its service offering; Ampersand also supported the appointment of Randall Sword as President and CEO while co-founders remain shareholders.

Ampersand Capital Partners Invests in Syft Technologies

April 18, 2022

Manufacturing

Ampersand Capital Partners made a minority growth equity investment in Syft Technologies Limited to accelerate the company's progress in the semiconductor market and develop scalable opportunities in life sciences. The investment will also bring Ampersand partner David Patteson to Syft’s board to support commercial growth and scale-up.

Ampersand Capital Partners Invests in Alliance Pharma

November 18, 2021

Healthcare Services

Ampersand Capital Partners has made a growth equity investment in Alliance Pharma, a Malvern, Pennsylvania–based bioanalytical CRO. The funding will support Alliance’s expansion of global reach, scientific capabilities, and operational capacity while founder Frank Li remains a significant shareholder.

Ampersand Capital Partners Majority Recapitalizes New England Peptide

October 7, 2019

Biotechnology

Ampersand Capital Partners completed a majority recapitalization of New England Peptide to support the company's worldwide growth initiatives and expand its peptide synthesis capabilities. As part of the transaction, Dr. José de Chastonay was appointed Executive Chairman; founders Sam and Jennifer Massoni remain noted in the announcement.